Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical RARE Stock

$16.70   5.031454%
Add to favorites
Market Cap
$1.70B
LOW - HIGH [24H]
$15.65 - $16.74
VOLUME [24H]
$5.59M
P/E Ratio
0
Earnings per share
-$5.17
ISIN
US90400D1081
Price   Prediction

Ultragenyx Pharmaceutical Price Chart

Sorry, that's all we've gotfor now...

Ultragenyx Pharmaceutical (RARE) stock price today is 16.7 USD on Tech Market Large (+5.03% on the day). Updated .

Ultragenyx Pharmaceutical RARE Financial and Trading Overview

Ultragenyx Pharmaceutical stock price 16.7 USD
Previous Close 16.08 USD
Open 15.88 USD
Bid 11.79 USD x 200
Ask 20.28 USD x 200
Day's Range 15.79 - 16.39 USD
52 Week Range 12.73 - 39.89 USD
Volume 5.25M USD
Avg. Volume 4.54M USD
Market Cap 1.62B USD
Beta (5Y Monthly) 0.357
PE Ratio (TTM) N/A
EPS (TTM) -5.17 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 24.8 USD

RARE Valuation Measures

Enterprise Value 2.54B USD
Trailing P/E N/A
Forward P/E 11.099399
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 2.21999
Price/Book (mrq) N/A
Enterprise Value/Revenue 3.483
Enterprise Value/EBITDA -6.31

Trading Information

Ultragenyx Pharmaceutical Stock Price History

Beta (5Y Monthly) 0.357
52-Week Change -50.58%
S&P500 52-Week Change 13.32%
52 Week High 39.89 USD
52 Week Low 12.73 USD
50-Day Moving Average 15.29 USD
200-Day Moving Average 22.53 USD

RARE Share Statistics

Avg. Volume (3 month) 4.54M USD
Avg. Daily Volume (10-Days) 4.16M USD
Shares Outstanding 101.92M
Float 77.44M
Short Ratio 6.81
% Held by Insiders 4.02%
% Held by Institutions 116.88%
Shares Short 23.62M
Short % of Float 23.94%
Short % of Shares Outstanding 23.17%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -71.78%
Operating Margin (ttm) -59.86%
Gross Margin -10.68%
EBITDA Margin -55.20%

Management Effectiveness

Return on Assets (ttm) -22.97%
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 730M USD
Revenue Per Share (ttm) 7.22 USD
Quarterly Revenue Growth (yoy) 8.09%
Gross Profit (ttm) -78000000 USD
EBITDA -403000000 USD
Net Income Avi to Common (ttm) -524000000 USD
Diluted EPS (ttm) -5.17
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 266M USD
Total Cash Per Share (mrq) 2.62 USD
Total Debt (mrq) 1.19B USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 1.398
Book Value Per Share (mrq) -3.701

Cash Flow Statement

Operating Cash Flow (ttm) -437000000 USD
Levered Free Cash Flow (ttm) -179376992 USD

Profile of Ultragenyx Pharmaceutical

Country United States
State CA
City Novato
Address 60 Leveroni Court
ZIP 94949
Phone 415 483 8800
Website https://www.ultragenyx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 1371

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Q&A For Ultragenyx Pharmaceutical Stock

What is a current RARE stock price?

Ultragenyx Pharmaceutical RARE stock price today per share is 16.7 USD.

How to purchase Ultragenyx Pharmaceutical stock?

You can buy RARE shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Ultragenyx Pharmaceutical?

The stock symbol or ticker of Ultragenyx Pharmaceutical is RARE.

Which industry does the Ultragenyx Pharmaceutical company belong to?

The Ultragenyx Pharmaceutical industry is Biotechnology.

How many shares does Ultragenyx Pharmaceutical have in circulation?

The max supply of Ultragenyx Pharmaceutical shares is 101.92M.

What is Ultragenyx Pharmaceutical Price to Earnings Ratio (PE Ratio)?

Ultragenyx Pharmaceutical PE Ratio is now.

What was Ultragenyx Pharmaceutical earnings per share over the trailing 12 months (TTM)?

Ultragenyx Pharmaceutical EPS is -5.17 USD over the trailing 12 months.

Which sector does the Ultragenyx Pharmaceutical company belong to?

The Ultragenyx Pharmaceutical sector is Healthcare.

Ultragenyx Pharmaceutical RARE included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24328.38 USD —
-0.74
8.59B USD — 23989.09 USD — 24547.66 USD — — 8.59B USD —
us Dow Jones U.S. Biotechnology In DJUSBT US 3928.9 USD —
-0.62
107.62M USD — 3912.88 USD — 3953.11 USD — — 107.62M USD —
us US Tech Biotechnology Total Retu XNBI US 7668.49 USD —
-0.71
— — 7593.62 USD — 7712.43 USD — — — —
us US Tech US 700 Small Cap Index NQUS700SC US 2927.58 USD —
-1.41
— — 2921.41 USD — 2969.11 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Composite Total Return XCMP US 30064.18 USD —
-0.74
— — 29644.9 USD — 30335.16 USD — — — —
us US Tech Global Select Market Com NQGS US 11984.26 USD —
-0.73
— — 11815.78 USD — 12090.12 USD — — — —
us US Tech Biotechnology NBI US 7017.81 USD —
-0.71
— — 6949.3 USD — 7058.02 USD — — — —
us US Tech Health Care IXHC US 1332.89 USD —
-0.73
— — 1323.81 USD — 1342.94 USD — — — —
$2.23T
Total marketcap
$79.97B
Total volume
BTC 58.48%   •   ETH 9.97%
Dominance
Select currency